Log in

ASX:ATXAmplia Therapeutics Stock Price, Forecast & News

A$0.08
0.00 (0.00 %)
(As of 05/13/2020)
Add
Compare
Today's Range
A$0.08
Now: A$0.08
A$0.09
50-Day Range
A$0.08
MA: A$0.08
A$0.08
52-Week Range
A$0.05
Now: A$0.08
A$0.34
Volume77,249 shs
Average VolumeN/A
Market Capitalization$5.52 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Amplia Therapeutics Limited, a pharmaceutical company, focuses on advancing a pipeline of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its clinical development pipeline comprises two lead molecules, AMP945 and AMP886 that inhibits FAK. The company also manufactures and sells drugs. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is headquartered in North Melbourne, Australia.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 3.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.89 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone61 2 8003 3650

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$34,227.00
Cash FlowA$0.02 per share
Book ValueA$0.13 per share

Profitability

Miscellaneous

EmployeesN/A
Market Cap$5.52 million
Next Earnings DateN/A
OptionableNot Optionable

Receive ATX News and Ratings via Email

Sign-up to receive the latest news and ratings for ATX and its competitors with MarketBeat's FREE daily newsletter.

Amplia Therapeutics (ASX:ATX) Frequently Asked Questions

How has Amplia Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Amplia Therapeutics' stock was trading at A$0.08 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ATX shares have increased by 10.7% and is now trading at A$0.08. View which stocks have been most impacted by Coronavirus.

Has Amplia Therapeutics been receiving favorable news coverage?

News coverage about ATX stock has trended negative on Sunday, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Amplia Therapeutics earned a daily sentiment score of -2.4 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View the latest news about Amplia Therapeutics.

Who are some of Amplia Therapeutics' key competitors?

Who are Amplia Therapeutics' key executives?

Amplia Therapeutics' management team includes the following people:
  • Dr. John Lambert, Chief Exec. Officer
  • Mr. Jeff Carter MAppFin, BFinAdmin, Chief Financial Officer (Age 61)
  • Mr. Andrew J. Cooke L.L.B., LLB, FAICS, MAICD, FGIA, FCIS, Company Sec. & Independent Non-Exec. Director (Age 59)
  • Mark Devlin, Chief Scientific Advisor
  • Dr. Frank Gelder, Founding Scientist

What is Amplia Therapeutics' stock symbol?

Amplia Therapeutics trades on the ASX under the ticker symbol "ATX."

What is Amplia Therapeutics' stock price today?

One share of ATX stock can currently be purchased for approximately A$0.08.

How big of a company is Amplia Therapeutics?

Amplia Therapeutics has a market capitalization of $5.52 million and generates $34,227.00 in revenue each year.

What is Amplia Therapeutics' official website?

The official website for Amplia Therapeutics is www.ampliatx.com.

How can I contact Amplia Therapeutics?

The company can be reached via phone at 61 2 8003 3650.

This page was last updated on 7/5/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.